0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Postmarketing Surveillance and Black Box Warnings—Reply

Robert J. Temple, MD; Martin H. Himmel, MD, MPH
JAMA. 2002;288(8):955-959. doi:10.1001/jama.288.8.955.
Text Size: A A A
Published online

Extract

In Reply: As Dr Graham, Dr Goldman, and Drs Greene and La Vaque point out, the population treated with a drug is more diverse than the population in which it was initially studied. Nonetheless, the most serious ADRs, such as those identified by Lasser et al,1 seem best explained by the much more extensive use after marketing and not by the greater diversity or comorbidity of the treated population, with some important exceptions. In premarketing clinical trials, drugs known to interact with the test drug would be scrupulously avoided; this avoidance is not ensured once the drug is marketed. In addition, few new drugs are studied in pregnant women. Of the ADRs identified by Lasser et al leading to box warnings or withdrawal, few (perhaps suprofen, used in dehydrated patients or some of the QT-prolonging drugs, used in patients with prolonged QT prior to taking the drug) seem principally related to the larger numbers of people receiving drugs in society.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();